Alnylam Pharmaceuticals Inc investor relations material

Alnylam Pharmaceuticals, Inc. is a US-based biopharmaceutical company. The company is engaged in discovering, developing, and commercializing novel therapeutics. Alnylam focuses on the use of RNAi technologies for therapeutic purposes across a range of human diseases. Alnylam markets Onpattro for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company recently launched LOXO-305 under an exclusive license from Loxo Oncology, a wholly-owned subsidiary of Eli Lilly and Company.